Search

CN-122005739-A - Pharmaceutical composition for preventing and treating inflammatory bowel disease, and preparation method and application thereof

CN122005739ACN 122005739 ACN122005739 ACN 122005739ACN-122005739-A

Abstract

The invention discloses a pharmaceutical composition for preventing and treating inflammatory bowel disease, and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine modernization. The pharmaceutical composition comprises the following active ingredients, by weight, 5-30 parts of turmeric, 4-30 parts of green tea, 3-20 parts of licorice, 5-30 parts of poria cocos, and 2-20 parts of cinnamon. The pharmaceutical composition acts on inflammatory factors such as TNF-alpha, IL-1 beta, IL-6 and the like by regulating key signal paths such as NF-kappa B, IL-17 and the like, plays a remarkable anti-inflammatory role, has the ability of scavenging ABTS free radicals and reducing iron ions, effectively reduces oxidative stress injury caused by inflammation, can remarkably inhibit release of LPS-induced lactate dehydrogenase, and reduces mRNA expression level of pro-inflammatory factors. The invention provides firm experimental basis and wide application prospect for developing safe and efficient inflammatory bowel disease treatment medicines with clear mechanisms.

Inventors

  • Guan Tiandu
  • FENG YINING
  • XIONG DAN
  • LIU MENGRU
  • RAO SHENGQI
  • YANG ZHENQUAN

Assignees

  • 扬州大学

Dates

Publication Date
20260512
Application Date
20260413

Claims (10)

  1. 1. The pharmaceutical composition for preventing and treating inflammatory bowel disease is characterized by comprising, by weight, 5-30 parts of turmeric, 4-30 parts of green tea, 3-20 parts of licorice, 5-30 parts of poria and 2-20 parts of cinnamon.
  2. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises, by weight, 10-25 parts of turmeric, 8-20 parts of green tea, 6-15 parts of licorice, 12-30 parts of poria and 4-10 parts of cinnamon.
  3. 3. A method of preparing a pharmaceutical composition according to claim 1 or 2, comprising: mixing the raw materials, pulverizing, soaking in solvent, and performing ultrasonic-assisted extraction to obtain extractive solution; Filtering the extract, and drying the filtrate to obtain the pharmaceutical composition.
  4. 4. The method according to claim 3, wherein the fine powder having a particle diameter of 150 μm to 250 μm is obtained by the pulverization.
  5. 5. The preparation method of the water-based composite material according to claim 3, wherein the solvent is water or ethanol water solution, the volume concentration of the ethanol water solution is 65% -75%, the solid-liquid ratio is 1 (10-20), and the soaking time is 10-14 h.
  6. 6. The preparation method of the ultrasonic-assisted extraction device according to claim 3, wherein the ultrasonic-assisted extraction is carried out at a temperature of 30-50 ℃ for 60-100 min, the drying is vacuum freeze drying, the drying temperature is-40-60 ℃, and the drying time is 68-75 h.
  7. 7. A pharmaceutical formulation for the prevention and treatment of inflammatory bowel disease, comprising the pharmaceutical composition of claim 1 or 2 and pharmaceutically acceptable excipients.
  8. 8. The pharmaceutical preparation according to claim 7, wherein the pharmaceutical preparation is in the form of decoction, granule, tablet, capsule, oral liquid, powder or pill, and the pharmaceutically acceptable auxiliary materials are one or more of filler, disintegrating agent, adhesive, lubricant, correctant, preservative or suspending agent.
  9. 9. Use of a pharmaceutical composition according to claim 1 or 2 or a pharmaceutical formulation according to claim 7 or 8 for the manufacture of a medicament for the prevention and treatment of inflammatory bowel disease.
  10. 10. The application of claim 9, wherein the application comprises at least one of: (1) Preparing a medicament that inhibits the expression of a pro-inflammatory cytokine selected from TNF- α, IL-1β and IL-6; (2) Preparing a medicament for scavenging free radicals or resisting oxidation; (3) Preparing a medicament for inhibiting the release of lactate dehydrogenase; (4) Preparing medicines for regulating NF- κB signaling pathway and/or IL-17 signaling pathway.

Description

Pharmaceutical composition for preventing and treating inflammatory bowel disease, and preparation method and application thereof Technical Field The invention relates to the technical field of modernization of traditional Chinese medicines, in particular to a pharmaceutical composition for preventing and treating inflammatory bowel diseases, a preparation method and application thereof. Background Inflammation is a defense mechanism of the immune system against infection, injury or foreign matter, mediated primarily by immune cells (e.g., macrophages, neutrophils, T cells), by secreting pro-inflammatory cytokines (e.g., TNF- α, IL-1β, IL-6) to clear pathogens and initiate tissue repair. However, dysregulation of inflammation can lead to chronic diseases such as inflammatory bowel disease, rheumatoid arthritis, and sepsis. Inflammatory bowel disease (Inflammatory Bowel Disease, IBD) is a complex disease characterized by chronic, non-specific inflammation of the gut, the pathogenesis of which involves the interaction of multiple factors such as immune system abnormalities, gut barrier dysfunction and oxidative stress. Studies have shown that over-expression of pro-inflammatory factors such as TNF-alpha, IL-1 beta and IL-6 are the core driving chronic inflammation, directly leading to tissue damage. At the same time, oxidative stress induced by excessive free radicals in the intestine damages epithelial cells, causing barrier dysfunction, which can be assessed by inhibition of Lactate Dehydrogenase (LDH) release. LDH is a marker enzyme in the cytoplasm, normally present in intact cells, and is released into the extracellular environment when the cell membrane breaks down due to oxidative damage. Therefore, inhibiting the release of LDH directly reflects the protective effect of the medicine on intestinal epithelial cells, and is a key index for alleviating tissue injury and promoting mucous membrane healing. From a deep mechanism, NF-. Kappa.B and IL-17 signaling pathways act as key hinges for regulating inflammatory responses, and their abnormal activation is the root cause of the above-mentioned pathological processes. In the pathogenesis of IBD, macrophages recognize pathogens (e.g., LPS) through pattern recognition receptors (e.g., TLR 4), activating NF- κb signaling pathways, thereby amplifying cytokine production, resulting in tissue damage. Currently, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are often used clinically to treat IBD, and although having significant anti-inflammatory effects, long-term use is often accompanied by serious side effects such as gastrointestinal damage, immunosuppression, metabolic disorders, and the like. Traditional Chinese Medicine (TCM) compounds are receiving increasing attention for their multicomponent synergism. Traditional Chinese medicine has unique theoretical and practical advantages in treating digestive system diseases. The traditional Chinese medicine considers that IBD belongs to the categories of diarrhea, acute appendicitis and the like, and the pathogenesis is spleen deficiency and excessive dampness, damp heat accumulation, qi stagnation and blood stasis. At present, partial researches and researches are performed to explore the application of a single traditional Chinese medicine extract or a simple compound in the treatment of inflammatory bowel disease, but the single traditional Chinese medicine extract has the defects of single action target point, limited curative effect and difficulty in comprehensively covering the complex pathological mechanism of the inflammatory bowel disease, and the traditional Chinese medicine compound has the defects of complex components, undefined compatibility logic, lack of specific preparation process optimization, low extraction rate of active ingredients, poor stability, incapability of fully playing the synergistic effect of each component and difficulty in meeting clinical prevention and treatment requirements. Therefore, searching for a novel prevention and treatment drug which has definite curative effect, small side effect, multi-target synergistic effect and suitability for long-term administration has become a research hotspot in the current IBD treatment field. Disclosure of Invention Aiming at the defects of the prior art, the invention provides a pharmaceutical composition (called 'JHQYY') based on turmeric (Curcuma longa), green tea (Green tea), licorice (Licorice), poria cocos (Poria cocos) and Cinnamon (Cinnamon), which has remarkable anti-inflammatory and antioxidant activities through multi-target and multi-channel synergistic effects, and can effectively prevent and treat inflammatory bowel diseases. The invention provides a pharmaceutical composition for preventing and treating inflammatory bowel disease, which comprises, by weight, 5-30 parts of turmeric, 4-30 parts of green tea, 3-20 parts of licorice, 5-30 parts of poria and 2-20 parts of cinnamon. The pharmaceutical compos